Seven abstracts featuring Exelixis compounds will be presented at ASCO's annual meeting from May 29 to June 2, 2009.
Links to data available at time of presentation.
| ASCO Abstract Number |
ASCO Abstract Title |
Presentation Date & Time (EDT) |
| 3512 |
A Phase 1 study of XL228, a potent IGF1R / AURORA / SRC inhibitor, in patients with solid tumors or hematologic malignancies
Data |
Saturday, May 30
4:15 p.m. |
| 3513 |
A Phase 1 study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors
Data |
Saturday, May 30
4:30 p.m. |
| |
|
|
| 2047 |
A Phase 2 study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse
Data |
Sunday, May 31
8 a.m.-noon |
| 2048 |
Use of neurovascular imaging in GBM patients (pts) to quantify early physiologic changes after treatment with XL184, an inhibitor of multiple receptor tyrosine kinases: results from a Phase 2 study
Data |
Sunday, May 31
8 a.m.-noon |
| 2049 |
Correlative tumor molecular profiling and plasma biomarker analysis in a Phase 2 study of XL184 in patients with progressive or recurrent glioblastoma multiforme (GBM)
Data |
Sunday, May 31
8 a.m.-noon |
| |
|
|
| 3500 |
Phase 1 dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors
Data |
Monday, June 1
1:30 p.m. |
| 3502 |
A Phase 1 dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors
Data |
Monday, June 1
2:00 p.m. |
